Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Detection Of Anal Hsil In A Routine Colonoscopy

Related Conditions

Often studied with 10 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 3 (1)

Trial Status

Active Not Recruiting1
Unknown1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06465914Phase 3Active Not Recruiting

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males

NCT05518201Phase 1Completed

Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old

NCT05060640Unknown

ANAL PRECANCEROUS LESIONS IN HIGH-RISK PATIENTS.

Showing all 3 trials

Research Network

Common Treatments

  • Detection Of Anal Hsil In A Routine Colonoscopy1
  • 9valent Human Papillomavirus Types 6 11 16 18 31 33 45 52 And 58 Recombinant Vaccine Hansenula Polymorpha1

Active Sponsors

  • Shanghai Bovax Biotechnology Co., Ltd.2
  • University Fernando Pessoa1

Top Investigators

Related Conditions

  • Ain33
  • Penile Cancer2
  • Pin22
  • Pin32
  • Pin12

Activity Timeline